You are here: Industry Insights > Ascletis

News List

Ascletis Receives IND Approval for its HIV Drug ASC09F prnasia
April 13, 2020
Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from National Medical Products Administration (NMPA) for its human immunodeficiency virus (HIV) protease inhibitor ASC09F (ASC09/Ritonavir Fixed-Dose Combination).
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA prnasia
February 18, 2020
Ascletis Pharma Inc. (HKEX code: 1672) announces today the application for in-house developed Category 1 Drug ASC41 for clinical trials of NASH indication has been accepted by China's National Medical Products Administration (NMPA).
Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout En-CPhI.CN
December 02, 2019
Ascletis Pharma Inc., an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral ...
Ascletis appoints new Chief Scientific Officer biospectrumasia
October 09, 2019
Dr. He was a former Global Head of Computational, Biopharmaceutics and Translational PK/PD at Novartis Pharmaceutical Corporation, New Jersey, USA.
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer En-CPhI.CN
October 08, 2019
Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral ...
Ascletis receives IND approval for its NASH drug biospectrumasia
August 28, 2019
ASC40 is an orally bioavailable, first-in-class inhibitor of fatty acid synthase (FASN)
Ascletis Received IND Approval and Management Outlook of 2019 and Beyond prnasia
August 06, 2019
Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and ...
Ascletis brings Former MSD Global VP on board biospectrumasia
March 04, 2019
Ascletis appoints Former MSD Global Vice President Dr. Zhengqing Li as Chief Medical Officer and President of R&D Greater China
Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases pharmafocusasia
January 17, 2019
Ascletis Pharma Inc and Suzhou Alphamab Co., Ltd. (Alphamab) jointly announce today that Ascletis' subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing agreement for .....
Ascletis and Roche enter exclusive Pegasys partnership in China for viral Hepatitis pharmafocusasia
November 26, 2018
hanghai Roche Pharmaceuticals Ltd. (Roche) and Ascletis BioScience Co., Ltd. (Ascletis, listed parent company stock code 1672.HK) jointly announce that....

Previous page 1 2 3 4 5 Next page